Lung cancer drug study aims to outsmart resistance
NCT ID NCT03586453
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tests the targeted drug osimertinib (Tagrisso) in 30 people with advanced EGFR-mutant non-small cell lung cancer who have not had prior EGFR inhibitor treatment. The main goal is to understand why the drug stops working by comparing tumor samples taken before and after treatment. Participants receive osimertinib and undergo biopsies to track resistance mechanisms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.